A novel 1,2-benzenediamine derivative FC-99 suppresses TLR3 expression and ameliorates disease symptoms in a mouse model of sepsis

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4866-4878

  Gong, Wei ^a   Hu, Erling ^a   Dou, Huan ^a   Song, Yuxian ^a   Yang, Liu ^a   Ji, Jianjian ^a   Li, Erguang ^a   Tan, Renxiang ^a   Hou, Yayi ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON REGULATORY FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; NEW DRUG; PHENYLENEDIAMINE DERIVATIVE; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; RANTES; STAT1 PROTEIN; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; [(4 METHOXY)METHYL] 4 METHYL 1,2 BENZENEDIAMINE; ALKANESULFONIC ACID; FLUORAD FC99; FLUOROCARBON; TLR3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CECUM LIGATION PUNCTURE; CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; MORTALITY; MOUSE; MOUSE MODEL; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PUNCTURE; RISK REDUCTION; SEPSIS; SHAM PROCEDURE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CECUM; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; KIDNEY; LIGATION; LIVER; LUNG; METABOLISM; PERITONEUM MACROPHAGE; PHYSIOLOGY; SURGERY; VIRUS REPLICATION;

ALKANESULFONATES; ANIMALS; CECUM; CELL LINE; FLUOROCARBONS; HUMANS; INTERLEUKIN-6; KIDNEY; LIGATION; LIVER; LUNG; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; RESPIRATORY SYNCYTIAL VIRUSES; SEPSIS; TOLL-LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

EID: 84919343557     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12797     Document Type: Article

References (46)

1. Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Alexander SPH, Ben son HE, Faccenda E, Pawson AJ, Sharman JL Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol, 170, 1676-1705.
3. Alexopoulou L, Holt AC, M edzhitov R, Flavell RA (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
4. Angus DC (2011). The search for effective therapy for sepsis: back to the drawing board? JAMA 306: 2614-2615.
5. Bianchi ME (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81: 1-5.
6. Boyd JH (2012). Toll-like recepto rs and opportunities for new sepsis therapeutics. Curr Infect Dis Rep 14: 455-461.
7. Brentano F, Kyburz D, Schorr O, Gay R, Gay S (2005). The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 233: 90-96.
8. Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW et al. (2008). TLR3 is an endogenous sensor of tissue necrosis during acute inflammato ry events. J Exp Med 205: 2609-2621.
9. Chen GY, Nunez G (2010). Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837.
10. Coquery CM, Loo W, Buszko M, Lannigan J, Erickson LD (2012). Optimized protocol for the isolation of spleen-resident murine neutrophils. Cytometry A 81: 806-814.
11. Dear JW, Yasuda H, Hu X, Hieny S, Yuen PS, Hewitt SM et al. (2006). Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int 69: 832-836.
12. Doughty LA, Carlton S, Galen B, Cooma-Ramberan I, Chung CS, Ayala A (2006). Activation of common antiviral pathways can potentiate inflammatory responses to septic shock. Shock 26: 187-194.
13. Gao M, Ha T, Zhang X, Liu L, Wang X, Kelley J et al. (2012). Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 40: 2390-2399.
14. Gong W,Dou H,Liu XQ,Sun LY,Hou YY 2012) Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-kappa B ligand-induced osteoclastogenesis Clin Exp Pharmacol Physiol 39, 886-893.
15. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW (2006). Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 176: 1733-1740.
16. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Muller M, Krause SW et al. (2003). Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278: 21502-21509.
17. Hutchens M, Luker KE, Sottile P, Sonstein J, Lukacs NW, Nunez G et al. (2008). TLR3 increases disease morbidity and mortality from vaccinia infection. J Immunol 180: 483-491.
18. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
19. Kawai T, Akira S (2006). Innate immune recognition of viral infection. Nat Immunol 7: 131-137.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
21. Kim KW, Cho ML, Oh HJ, Kim HR, Kang CM, Heo YM et al. (2009). TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett 124: 9-17.
22. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R et al. (2006). Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2: e53.
23. Levy MM, Fink MP, M arshall JC, Abraham E, Angus D, Cook D et al. (2003). 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256.
24. Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X (2008). CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood 112: 4961-4970.
25. Marshak-R othstein A (2006). Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
26. Matsumoto M, Seya T (2008). TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60: 805-812.
27. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS et al. (2010). Mesenc hymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 182: 1047-1057.
29. Murray LA, Knight DA, McAlonan L, Argentieri R, Joshi A, Shaheen F et al. (2008). Deleterious role of TLR3 during hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 178: 1227-1237.
30. Okahira S, Nishikawa F, Nishikawa S, Akazawa T, Seya T, Matsumoto M (2005). Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol 24: 614-623.
31. O'Neill LA, Bryant CE, Doyle SL (2009). Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61: 177-197.
32. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106.
33. Perales-Linares R, Navas-Martin S (2013). Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology 140: 153-167.
34. Russell JA (2006). Management of sepsis. N Engl J Med 355: 1699-1713.
35. Savva A,Roger T (2013) Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-Associated pathology and infectious diseases Front Immunol 4, 387.
36. Tsujimoto H, Ono S, Majima T, Kawarabayashi N, Takayama E, Kinoshita M et al. (2005). Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 23: 39-44.
37. Tsujimoto H, Ono S, Matsumoto A, Kawabata T, Kinoshita M, M ajima T et al. (2006). A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells. J Hepatol 45: 836-843.
38. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H (2008). Role of Toll-like receptors in the development of sepsis. Shock 29: 315-321.
39. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E , Flavell RA (2004). Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10: 1366-1373.
40. Ward PA (2012). New approaches to the study of sepsis. EMBO Mol Med 4: 1234-1243.
41. Williams DL, Ha T, Li C, Kalbfleisch JH, Schweitzer J, Vogt W et al. (2003). Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 31: 1808-1818.
42. Xie H, Hua C, Sun L, Zhao X, Fan H, Dou H et al. (2011). 17beta-estradiol induces CD40 expression in dendritic cells via MAPK signaling pathways in a minichromosome maintenance protein 6-dependent manner. Arthritis Rheum 63: 2425-2435.
43. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S et al. (2008). Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 294: F1050-F1058.
44. Yu L, Wang L, Chen S (2010). Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 14: 2592-2603.
45. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P et al. (2007). TLR3 deficiency in patients with herpes simplex encephalitis. Science 317: 1522-1527.
46. Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L et al. (2013). Poly(I:C) Improves MSCs immune function: the toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem c ells on sepsis via inhibiting miR-143. Stem Cells 32: 521-533.